Innovaccer has 6 close competitors: Alloy Therapeutics, Abridge, Commure.
Sector, valuation and status for each competitor.
company profile›
competitor›
competitor›
competitor›
competitor›A private valuation and a public market cap share one column; each row names its basis and date.
InnovaccerAbridgeCommureHeartFlowNeuralinkAmerican healthcare technology company offering an agentic AI platform that unifies clinical, operational and financial data across health systems, payers, government health agencies and life sciences organizations.
Innovaccer competes with 6 companies here: Alloy Therapeutics, Abridge, Commure, HeartFlow, HistoSonics, Neuralink.
Innovaccer was last valued at $3.5B (post-money, Jan 2025). That price was agreed in one transaction and holds until the next round. A listed competitor is repriced every trading session.
The routes section explains what is realistically available for a company at this stage.
No. Innovaccer is a private company; its shares do not trade on a public exchange.
The last valuation is $3.5B.
Lead investors for each round are in the funding timeline.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
